{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:21:14Z","timestamp":1792646474905,"version":"4.5.0"},"reference-count":66,"publisher":"Harborside Press, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Definitive radiation therapy is the backbone of treatment in the management of primary vaginal cancer. The use of modern treatment techniques, such as intensity-modulated radiotherapy (RT) and image-guided adaptive brachytherapy, allows for the precise delivery of higher radiation doses to the tumor with reduced exposure to surrounding normal tissues compared with older, conventional 2D techniques. These advances in treatment planning have resulted in a nearly 10% absolute improvement in survival, along with a significant reduction in severe treatment-related toxicity. Accurate target volume delineation based on the tumor location and extent at presentation is crucial and is achieved with greater precision due to advances in imaging, including the routine incorporation of MRI into treatment planning. The brachytherapy target volume concepts used in the management of vaginal cancers largely mirror the adaptive approaches established for cervical cancers, incorporating tumor response following external-beam RT. Additionally, the expanding array of brachytherapy applicators, including both hybrid and custom options, has improved the ease and conformality of tumor implantation compared with standard template-based approaches. This review summarizes modern RT concepts and techniques in the management of primary vaginal cancer.<\/jats:p>","DOI":"10.6004\/jnccn.2026.7013","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:31:23Z","timestamp":1773318683000},"source":"Crossref","is-referenced-by-count":2,"title":["Modern Radiation Therapy Techniques for Vaginal Carcinoma"],"prefix":"10.6004","volume":"24","author":[{"given":"Christine","family":"Chin","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Nuvance Health, Norwalk, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Damast","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Crit Rev Oncol Hematol","first-page":"286","article-title":"Vaginal cancer","volume":"81","author":"Di Donato V","year":"2012","unstructured":"Di Donato V, Bellati F, Fischetti M,  Vaginal cancer. Crit Rev Oncol Hematol 2012;81:286\u2013295."},{"key":"B2","series-title":"BJOG","first-page":"1660","article-title":"Incidence distributions, risk factors and trends of vaginal cancer: a global population-based study","volume":"131","author":"Huang J","year":"2024","unstructured":"Huang J, Chan SC, Pang WS,  Incidence distributions, risk factors and trends of vaginal cancer: a global population-based study. BJOG 2024;131:1660\u20131672."},{"key":"B3","series-title":"Int J Gynecol Cancer","first-page":"344","article-title":"Updates in the treatment of vaginal cancer","volume":"32","author":"Jhingran A","year":"2022","unstructured":"Jhingran A. Updates in the treatment of vaginal cancer. Int J Gynecol Cancer 2022;32:344\u2013351."},{"key":"B4","series-title":"Radiother Oncol","first-page":"109662","article-title":"ESTRO\/ESGO\/SIOPe guidelines for the management of patients with vaginal cancer","volume":"186","author":"Nout RA","year":"2023","unstructured":"Nout RA, Calaminus G, Planchamp F,  ESTRO\/ESGO\/SIOPe guidelines for the management of patients with vaginal cancer. Radiother Oncol 2023;186:109662."},{"key":"B5","series-title":"Eur J Cancer","first-page":"2846","article-title":"Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples","volume":"50","author":"Alemany L","year":"2014","unstructured":"Alemany L, Saunier M, Tinoco L,  Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer 2014;50:2846\u20132854."},{"key":"B6","series-title":"Int J Radiat Oncol Biol Phys","first-page":"138","article-title":"Definitive radiation therapy for squamous cell carcinoma of the vagina","volume":"62","author":"Frank SJ","year":"2005","unstructured":"Frank SJ, Jhingran A, Levenback C,  Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 2005;62:138\u2013147."},{"key":"B7","series-title":"Gynecol Oncol","first-page":"501","article-title":"Brachytherapy improves survival in primary vaginal cancer","volume":"141","author":"Orton A","year":"2016","unstructured":"Orton A, Boothe D, Williams N,  Brachytherapy improves survival in primary vaginal cancer. Gynecol Oncol 2016;141:501\u2013506."},{"key":"B8","series-title":"Gynecol Oncol","first-page":"35","article-title":"Brachytherapy in vaginal cancer for organ preservation: clinical outcome and safety from a single enter experience","volume":"190","author":"Merten R","year":"2024","unstructured":"Merten R, Strnad V, Karius A,  Brachytherapy in vaginal cancer for organ preservation: clinical outcome and safety from a single enter experience. Gynecol Oncol 2024;190:35\u201341."},{"key":"B9","series-title":"Brachytherapy","first-page":"75","article-title":"The impact of brachytherapy boost and radiotherapy treatment duration on survival in patients with vaginal cancer treated with definitive chemoradiation","volume":"20","author":"Reshko LB","year":"2021","unstructured":"Reshko LB, Gaskins JT, Metzinger DS,  The impact of brachytherapy boost and radiotherapy treatment duration on survival in patients with vaginal cancer treated with definitive chemoradiation. Brachytherapy 2021;20:75\u201384."},{"key":"B10","series-title":"Lancet Oncol","first-page":"e157","article-title":"Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer","volume":"21","author":"Westerveld H","year":"2020","unstructured":"Westerveld H, Nesvacil N, Fokdal L,  Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer. Lancet Oncol 2020;21:e157\u2013167."},{"key":"B11","series-title":"Gynecol Oncol","first-page":"456","article-title":"Management and outcomes of primary vaginal cancer","volume":"159","author":"Yang J","year":"2020","unstructured":"Yang J, Delara R, Magrina J,  Management and outcomes of primary vaginal cancer. Gynecol Oncol 2020;159:456\u2013463."},{"key":"B12","series-title":"J Clin Oncol","first-page":"1685","article-title":"Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: a report from the NRG oncology RTOG 1203 study","volume":"38","author":"Yeung AR","year":"2020","unstructured":"Yeung AR, Pugh SL, Klopp AH,  Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: a report from the NRG oncology RTOG 1203 study. J Clin Oncol 2020;38:1685\u20131692."},{"key":"B13","series-title":"Cancers (Basel)","first-page":"1459","article-title":"Image-guided adaptive brachytherapy (IGABT) for primary vaginal cancer: results of the international multicenter RetroEMBRAVE cohort study","volume":"13","author":"Westerveld H","year":"2021","unstructured":"Westerveld H, Schmid MP, Nout RA,  Image-guided adaptive brachytherapy (IGABT) for primary vaginal cancer: results of the international multicenter RetroEMBRAVE cohort study. Cancers (Basel) 2021;13:1459."},{"key":"B14","series-title":"Radiother Oncol","first-page":"428","article-title":"Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in Retro EMBRACE, a multicenter cohort study","volume":"120","author":"Sturdza A","year":"2016","unstructured":"Sturdza A, P\u00f6tter R, Fokdal LU,  Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in Retro EMBRACE, a multicenter cohort study. Radiother Oncol 2016;120:428\u2013433."},{"key":"B15","series-title":"Lancet Oncol","first-page":"538","article-title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study","volume":"22","author":"Potter R","year":"2021","unstructured":"Potter R, Tanderup K, Schmid MP,  MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol 2021;22:538\u2013547."},{"key":"B16","series-title":"Clin Transl Radiat Oncol","first-page":"48","article-title":"The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies","volume":"9","author":"Potter R","year":"2018","unstructured":"Potter R, Tanderup K, Kirisits C,  The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol 2018;9:48\u201360."},{"key":"B17","series-title":"Int J Radiat Oncol Biol Phys","first-page":"733","article-title":"FDG-PET evaluation of vaginal carcinoma","volume":"62","author":"Lamoreaux WT","year":"2005","unstructured":"Lamoreaux WT, Grigsby PW, Dehdashti F,  FDG-PET evaluation of vaginal carcinoma. Int J Radiat Oncol Biol Phys 2005;62:733\u2013737."},{"key":"B18","series-title":"Pract Radiat Oncol","first-page":"274","article-title":"Contouring inguinal and femoral nodes; how much margin is needed around the vessels?","volume":"2","author":"Kim CH","year":"2012","unstructured":"Kim CH, Olson AC, Kim H,  Contouring inguinal and femoral nodes; how much margin is needed around the vessels? Pract Radiat Oncol 2012;2:274\u2013278."},{"key":"B19","unstructured":"Abu-Rustum NR, Campos SM, Amarnath S, et al. NCCN Clinical Practice Guidelines in Oncology: Vaginal Cancer. Version 2.2026. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B20","series-title":"Gynecol Oncol","first-page":"495","article-title":"Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study","volume":"135","author":"Rajagopalan MS","year":"2014","unstructured":"Rajagopalan MS, Xu KM, Lin JF,  Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study. Gynecol Oncol 2014;135:495\u2013502."},{"key":"B21","series-title":"Brachytherapy","first-page":"282","article-title":"Design approach and benefits of the 3D-printed vaginal individualized applicator (VIA)","volume":"23","author":"Ewongwo A","year":"2024","unstructured":"Ewongwo A, Niedermayr T, Kidd E. Design approach and benefits of the 3D-printed vaginal individualized applicator (VIA). Brachytherapy 2024;23:282\u2013289."},{"key":"B22","series-title":"Radiother Oncol","first-page":"173","article-title":"Individualised 3D printed vaginal template for MRI guided brachytherapy in locally advanced cervical cancer","volume":"118","author":"Lindegaard JC","year":"2016","unstructured":"Lindegaard JC, Madsen ML, Traberg A,  Individualised 3D printed vaginal template for MRI guided brachytherapy in locally advanced cervical cancer. Radiother Oncol 2016;118:173\u2013175."},{"key":"B23","series-title":"J Contemp Brachytherapy","first-page":"470","article-title":"Inversely designed, 3D-printed personalized template-guided interstitial brachytherapy for vaginal tumors","volume":"10","author":"Sekii S","year":"2018","unstructured":"Sekii S, Tsujino K, Kosaka K,  Inversely designed, 3D-printed personalized template-guided interstitial brachytherapy for vaginal tumors. J Contemp Brachytherapy 2018;10:470\u2013477."},{"key":"B24","series-title":"Brachytherapy","first-page":"68","article-title":"Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer","volume":"11","author":"Beriwal S","year":"2012","unstructured":"Beriwal S, Demanes DJ, Erickson B,  Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer. Brachytherapy 2012;11:68\u201375."},{"key":"B25","series-title":"Pract Radiat Oncol","first-page":"277","article-title":"Anesthetic considerations for gynecologic high dose rate brachytherapy","volume":"15","author":"Remick JS","year":"2025","unstructured":"Remick JS, Fields EC, Bhatt BP. Anesthetic considerations for gynecologic high dose rate brachytherapy. Pract Radiat Oncol 2025;15:277\u2013283."},{"key":"B26","series-title":"Radiother Oncol","first-page":"36","article-title":"Recommendations from gynaecological (GYN) GEC-ESTRO working group \u2013 ACROP: target concept for image guided adaptive brachytherapy in primary vaginal cancer","volume":"145","author":"Schmid MP","year":"2020","unstructured":"Schmid MP, Fokdal L, Westerveld H,  Recommendations from gynaecological (GYN) GEC-ESTRO working group \u2013 ACROP: target concept for image guided adaptive brachytherapy in primary vaginal cancer. Radiother Oncol 2020;145:36\u201344."},{"key":"B27","series-title":"Radiother Oncol","first-page":"473","article-title":"Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept","volume":"100","author":"Fokdal L","year":"2011","unstructured":"Fokdal L, Tanderup K, Nielsen SK,  Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept. Radiother Oncol 2011;100:473\u2013479."},{"key":"B28","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1880","article-title":"Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results","volume":"82","author":"Dimopoulos JCA","year":"2012","unstructured":"Dimopoulos JCA, Schmid MP, Fidarova E,  Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results. Int J Radiat Oncol Biol Phys 2012;82:1880\u20131888."},{"key":"B29","series-title":"Brachytherapy","first-page":"571","article-title":"Image-guided adaptive brachytherapy in primary vaginal cancers: a monocentric experience","volume":"17","author":"Huertas A","year":"2018","unstructured":"Huertas A, Dumas I, Escande A,  Image-guided adaptive brachytherapy in primary vaginal cancers: a monocentric experience. Brachytherapy 2018;17:571\u2013579."},{"key":"B30","series-title":"Gynecol Oncol","first-page":"293","article-title":"Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina","volume":"150","author":"Gebhardt BJ","year":"2018","unstructured":"Gebhardt BJ, Vargo JA, Kim H,  Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina. Gynecol Oncol 2018;150:293\u2013299."},{"key":"B31","series-title":"Radiother Oncol","first-page":"486","article-title":"Outcomes with image-guided interstitial brachytherapy for vaginal cancer","volume":"120","author":"Manuel MM","year":"2016","unstructured":"Manuel MM, Cho LP, Catalano PJ,  Outcomes with image-guided interstitial brachytherapy for vaginal cancer. Radiother Oncol 2016;120:486\u2013492."},{"key":"B32","series-title":"Brachytherapy","first-page":"429","article-title":"Compendium of fractionation choices for gynecologic HDR brachytherapy\u2014an American Brachytherapy Society Task Group report","volume":"18","author":"Albuquerque K","year":"2019","unstructured":"Albuquerque K, Hrycushko BA, Harkenrider MM,  Compendium of fractionation choices for gynecologic HDR brachytherapy\u2014an American Brachytherapy Society Task Group report. Brachytherapy 2019;18:429\u2013436."},{"key":"B33","series-title":"Lancet","first-page":"1321","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Lorusso D","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K,  Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2024;404:1321\u20131332."},{"key":"B1","series-title":"Crit Rev Oncol Hematol","first-page":"286","article-title":"Vaginal cancer","volume":"81","author":"Di Donato V","year":"2012","unstructured":"Di Donato V, Bellati F, Fischetti M,  Vaginal cancer. Crit Rev Oncol Hematol 2012;81:286\u2013295."},{"key":"B2","series-title":"BJOG","first-page":"1660","article-title":"Incidence distributions, risk factors and trends of vaginal cancer: a global population-based study","volume":"131","author":"Huang J","year":"2024","unstructured":"Huang J, Chan SC, Pang WS,  Incidence distributions, risk factors and trends of vaginal cancer: a global population-based study. BJOG 2024;131:1660\u20131672."},{"key":"B3","series-title":"Int J Gynecol Cancer","first-page":"344","article-title":"Updates in the treatment of vaginal cancer","volume":"32","author":"Jhingran A","year":"2022","unstructured":"Jhingran A. Updates in the treatment of vaginal cancer. Int J Gynecol Cancer 2022;32:344\u2013351."},{"key":"B4","series-title":"Radiother Oncol","first-page":"109662","article-title":"ESTRO\/ESGO\/SIOPe guidelines for the management of patients with vaginal cancer","volume":"186","author":"Nout RA","year":"2023","unstructured":"Nout RA, Calaminus G, Planchamp F,  ESTRO\/ESGO\/SIOPe guidelines for the management of patients with vaginal cancer. Radiother Oncol 2023;186:109662."},{"key":"B5","series-title":"Eur J Cancer","first-page":"2846","article-title":"Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples","volume":"50","author":"Alemany L","year":"2014","unstructured":"Alemany L, Saunier M, Tinoco L,  Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer 2014;50:2846\u20132854."},{"key":"B6","series-title":"Int J Radiat Oncol Biol Phys","first-page":"138","article-title":"Definitive radiation therapy for squamous cell carcinoma of the vagina","volume":"62","author":"Frank SJ","year":"2005","unstructured":"Frank SJ, Jhingran A, Levenback C,  Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 2005;62:138\u2013147."},{"key":"B7","series-title":"Gynecol Oncol","first-page":"501","article-title":"Brachytherapy improves survival in primary vaginal cancer","volume":"141","author":"Orton A","year":"2016","unstructured":"Orton A, Boothe D, Williams N,  Brachytherapy improves survival in primary vaginal cancer. Gynecol Oncol 2016;141:501\u2013506."},{"key":"B8","series-title":"Gynecol Oncol","first-page":"35","article-title":"Brachytherapy in vaginal cancer for organ preservation: clinical outcome and safety from a single enter experience","volume":"190","author":"Merten R","year":"2024","unstructured":"Merten R, Strnad V, Karius A,  Brachytherapy in vaginal cancer for organ preservation: clinical outcome and safety from a single enter experience. Gynecol Oncol 2024;190:35\u201341."},{"key":"B9","series-title":"Brachytherapy","first-page":"75","article-title":"The impact of brachytherapy boost and radiotherapy treatment duration on survival in patients with vaginal cancer treated with definitive chemoradiation","volume":"20","author":"Reshko LB","year":"2021","unstructured":"Reshko LB, Gaskins JT, Metzinger DS,  The impact of brachytherapy boost and radiotherapy treatment duration on survival in patients with vaginal cancer treated with definitive chemoradiation. Brachytherapy 2021;20:75\u201384."},{"key":"B10","series-title":"Lancet Oncol","first-page":"e157","article-title":"Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer","volume":"21","author":"Westerveld H","year":"2020","unstructured":"Westerveld H, Nesvacil N, Fokdal L,  Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer. Lancet Oncol 2020;21:e157\u2013167."},{"key":"B11","series-title":"Gynecol Oncol","first-page":"456","article-title":"Management and outcomes of primary vaginal cancer","volume":"159","author":"Yang J","year":"2020","unstructured":"Yang J, Delara R, Magrina J,  Management and outcomes of primary vaginal cancer. Gynecol Oncol 2020;159:456\u2013463."},{"key":"B12","series-title":"J Clin Oncol","first-page":"1685","article-title":"Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: a report from the NRG oncology RTOG 1203 study","volume":"38","author":"Yeung AR","year":"2020","unstructured":"Yeung AR, Pugh SL, Klopp AH,  Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: a report from the NRG oncology RTOG 1203 study. J Clin Oncol 2020;38:1685\u20131692."},{"key":"B13","series-title":"Cancers (Basel)","first-page":"1459","article-title":"Image-guided adaptive brachytherapy (IGABT) for primary vaginal cancer: results of the international multicenter RetroEMBRAVE cohort study","volume":"13","author":"Westerveld H","year":"2021","unstructured":"Westerveld H, Schmid MP, Nout RA,  Image-guided adaptive brachytherapy (IGABT) for primary vaginal cancer: results of the international multicenter RetroEMBRAVE cohort study. Cancers (Basel) 2021;13:1459."},{"key":"B14","series-title":"Radiother Oncol","first-page":"428","article-title":"Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in Retro EMBRACE, a multicenter cohort study","volume":"120","author":"Sturdza A","year":"2016","unstructured":"Sturdza A, P\u00f6tter R, Fokdal LU,  Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in Retro EMBRACE, a multicenter cohort study. Radiother Oncol 2016;120:428\u2013433."},{"key":"B15","series-title":"Lancet Oncol","first-page":"538","article-title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study","volume":"22","author":"Potter R","year":"2021","unstructured":"Potter R, Tanderup K, Schmid MP,  MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol 2021;22:538\u2013547."},{"key":"B16","series-title":"Clin Transl Radiat Oncol","first-page":"48","article-title":"The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies","volume":"9","author":"Potter R","year":"2018","unstructured":"Potter R, Tanderup K, Kirisits C,  The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol 2018;9:48\u201360."},{"key":"B17","series-title":"Int J Radiat Oncol Biol Phys","first-page":"733","article-title":"FDG-PET evaluation of vaginal carcinoma","volume":"62","author":"Lamoreaux WT","year":"2005","unstructured":"Lamoreaux WT, Grigsby PW, Dehdashti F,  FDG-PET evaluation of vaginal carcinoma. Int J Radiat Oncol Biol Phys 2005;62:733\u2013737."},{"key":"B18","series-title":"Pract Radiat Oncol","first-page":"274","article-title":"Contouring inguinal and femoral nodes; how much margin is needed around the vessels?","volume":"2","author":"Kim CH","year":"2012","unstructured":"Kim CH, Olson AC, Kim H,  Contouring inguinal and femoral nodes; how much margin is needed around the vessels? Pract Radiat Oncol 2012;2:274\u2013278."},{"key":"B19","unstructured":"Abu-Rustum NR, Campos SM, Amarnath S, et al. NCCN Clinical Practice Guidelines in Oncology: Vaginal Cancer. Version 2.2026. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B20","series-title":"Gynecol Oncol","first-page":"495","article-title":"Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study","volume":"135","author":"Rajagopalan MS","year":"2014","unstructured":"Rajagopalan MS, Xu KM, Lin JF,  Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study. Gynecol Oncol 2014;135:495\u2013502."},{"key":"B21","series-title":"Brachytherapy","first-page":"282","article-title":"Design approach and benefits of the 3D-printed vaginal individualized applicator (VIA)","volume":"23","author":"Ewongwo A","year":"2024","unstructured":"Ewongwo A, Niedermayr T, Kidd E. Design approach and benefits of the 3D-printed vaginal individualized applicator (VIA). Brachytherapy 2024;23:282\u2013289."},{"key":"B22","series-title":"Radiother Oncol","first-page":"173","article-title":"Individualised 3D printed vaginal template for MRI guided brachytherapy in locally advanced cervical cancer","volume":"118","author":"Lindegaard JC","year":"2016","unstructured":"Lindegaard JC, Madsen ML, Traberg A,  Individualised 3D printed vaginal template for MRI guided brachytherapy in locally advanced cervical cancer. Radiother Oncol 2016;118:173\u2013175."},{"key":"B23","series-title":"J Contemp Brachytherapy","first-page":"470","article-title":"Inversely designed, 3D-printed personalized template-guided interstitial brachytherapy for vaginal tumors","volume":"10","author":"Sekii S","year":"2018","unstructured":"Sekii S, Tsujino K, Kosaka K,  Inversely designed, 3D-printed personalized template-guided interstitial brachytherapy for vaginal tumors. J Contemp Brachytherapy 2018;10:470\u2013477."},{"key":"B24","series-title":"Brachytherapy","first-page":"68","article-title":"Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer","volume":"11","author":"Beriwal S","year":"2012","unstructured":"Beriwal S, Demanes DJ, Erickson B,  Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer. Brachytherapy 2012;11:68\u201375."},{"key":"B25","series-title":"Pract Radiat Oncol","first-page":"277","article-title":"Anesthetic considerations for gynecologic high dose rate brachytherapy","volume":"15","author":"Remick JS","year":"2025","unstructured":"Remick JS, Fields EC, Bhatt BP. Anesthetic considerations for gynecologic high dose rate brachytherapy. Pract Radiat Oncol 2025;15:277\u2013283."},{"key":"B26","series-title":"Radiother Oncol","first-page":"36","article-title":"Recommendations from gynaecological (GYN) GEC-ESTRO working group \u2013 ACROP: target concept for image guided adaptive brachytherapy in primary vaginal cancer","volume":"145","author":"Schmid MP","year":"2020","unstructured":"Schmid MP, Fokdal L, Westerveld H,  Recommendations from gynaecological (GYN) GEC-ESTRO working group \u2013 ACROP: target concept for image guided adaptive brachytherapy in primary vaginal cancer. Radiother Oncol 2020;145:36\u201344."},{"key":"B27","series-title":"Radiother Oncol","first-page":"473","article-title":"Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept","volume":"100","author":"Fokdal L","year":"2011","unstructured":"Fokdal L, Tanderup K, Nielsen SK,  Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept. Radiother Oncol 2011;100:473\u2013479."},{"key":"B28","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1880","article-title":"Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results","volume":"82","author":"Dimopoulos JCA","year":"2012","unstructured":"Dimopoulos JCA, Schmid MP, Fidarova E,  Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results. Int J Radiat Oncol Biol Phys 2012;82:1880\u20131888."},{"key":"B29","series-title":"Brachytherapy","first-page":"571","article-title":"Image-guided adaptive brachytherapy in primary vaginal cancers: a monocentric experience","volume":"17","author":"Huertas A","year":"2018","unstructured":"Huertas A, Dumas I, Escande A,  Image-guided adaptive brachytherapy in primary vaginal cancers: a monocentric experience. Brachytherapy 2018;17:571\u2013579."},{"key":"B30","series-title":"Gynecol Oncol","first-page":"293","article-title":"Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina","volume":"150","author":"Gebhardt BJ","year":"2018","unstructured":"Gebhardt BJ, Vargo JA, Kim H,  Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina. Gynecol Oncol 2018;150:293\u2013299."},{"key":"B31","series-title":"Radiother Oncol","first-page":"486","article-title":"Outcomes with image-guided interstitial brachytherapy for vaginal cancer","volume":"120","author":"Manuel MM","year":"2016","unstructured":"Manuel MM, Cho LP, Catalano PJ,  Outcomes with image-guided interstitial brachytherapy for vaginal cancer. Radiother Oncol 2016;120:486\u2013492."},{"key":"B32","series-title":"Brachytherapy","first-page":"429","article-title":"Compendium of fractionation choices for gynecologic HDR brachytherapy\u2014an American Brachytherapy Society Task Group report","volume":"18","author":"Albuquerque K","year":"2019","unstructured":"Albuquerque K, Hrycushko BA, Harkenrider MM,  Compendium of fractionation choices for gynecologic HDR brachytherapy\u2014an American Brachytherapy Society Task Group report. Brachytherapy 2019;18:429\u2013436."},{"key":"B33","series-title":"Lancet","first-page":"1321","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Lorusso D","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K,  Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2024;404:1321\u20131332."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-e267013.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-e267013.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-e267013.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:31:23Z","timestamp":1773318683000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-e267013.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":66,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.7013","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}